Kroemer, Heyo Klaus

[["dc.bibliographiccitation.firstpage","8"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Pharmacogenetics and genomics"],["dc.bibliographiccitation.lastpage","18"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Meyer zu Schwabedissen, Henriette E."],["dc.contributor.author","Albers, Martin"],["dc.contributor.author","Baumeister, Sebastian E."],["dc.contributor.author","Rimmbach, Christian"],["dc.contributor.author","Nauck, Matthias"],["dc.contributor.author","Wallaschofski, Henri"],["dc.contributor.author","Siegmund, Werner"],["dc.contributor.author","Völzke, Henry"],["dc.contributor.author","Kroemer, Heyo K."],["dc.date.accessioned","2018-08-20T13:02:42Z"],["dc.date.available","2018-08-20T13:02:42Z"],["dc.date.issued","2015"],["dc.description.abstract","BACKGROUND: The efficacy of statins, which are used commonly in primary and secondary prevention of cardiovascular diseases, shows a wide range of interindividual variability. Genetic variants of OATP1B1, a hepatic uptake transporter, can modify access of statins to its therapeutic target, thereby potentially altering drug efficacy. We studied the impact of genetic variants of OATP1B1 on the lipid-lowering efficacy of statins in a population-based setting. MATERIALS AND METHODS: The basis of the analysis was the Study of Health in Pomerania, a cohort of 2732 men and women aged 20-81 years. Included in the statistical analysis to evaluate the impact of OATP1B1 on therapeutic efficacy of statins were 214 individuals diagnosed with dyslipidaemia during initial recruitment and receiving statins during the 5-year follow-up. RESULTS: Analysing the impact of the OATP1B1 genotype, we observed a trend for lower statin-induced total cholesterol reduction in carriers of the SLCO1B1 512C variant. Restricting the analysis to patients receiving simvastatin, pravastatin, lovastatin and fluvastatin indicated a statistically significant association of the OATP1B1 genotype on lipid parameters at the 5-year follow-up. No such effect was observed for atorvastatin. Calculation of achievement of treatment goals according to the NCEP-ATPIII guidelines showed a lower rate of successful treatment when harbouring the mutant allele for patients taking simvastatin (46.7 vs. 73.9%). A similar trend was observed for pravastatin (34.4 vs. 70.4%). CONCLUSION: Genetic variants of OATP1B1 leading to impaired hepatic uptake of statins translated into reduced drug efficacy in a population-based cohort."],["dc.identifier.doi","10.1097/FPC.0000000000000098"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15443"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1744-6872"],["dc.title","Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1405"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Metabolomics"],["dc.bibliographiccitation.lastpage","1415"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Friedrich, Nele"],["dc.contributor.author","Budde, Kathrin"],["dc.contributor.author","Suhre, Karsten"],["dc.contributor.author","Voelker, Uwe"],["dc.contributor.author","John, Ulrich"],["dc.contributor.author","Felix, Stephan B."],["dc.contributor.author","Kroemer, Heyo K."],["dc.contributor.author","Grabe, Hans Joergen"],["dc.contributor.author","Voelzke, Henry"],["dc.contributor.author","Nauck, Matthias"],["dc.contributor.author","Wallaschofski, Henri"],["dc.date.accessioned","2018-11-07T09:51:23Z"],["dc.date.available","2018-11-07T09:51:23Z"],["dc.date.issued","2015"],["dc.description.abstract","Recently research provides evidence that blood metabolite profiles predicted type 2 diabetes. We aimed to assess the relation of urine metabolites measured via nuclear magnetic resonance spectroscopy with incident type 2 diabetes in a sample of 1353 men and 1356 women. Within 5 years, 87 men and 50 women developed diabetes. Five and 16 urine metabolites were associated with incident diabetes in men and women, respectively. Only three of these metabolites (glucose, lactate and glycine) were found in both sexes. In women, e.g. acetate, carnitine, N,N-dimethylglycine, trigonelline, 3-hydroxyisovalerate, alanine, formate, glycolate, trimethylamine N-oxide and tau-methylhistidine were positively related with diabetes. Receiver operating characteristic (ROC) analysis revealed that compared with a standard model, a model additionally adjusted for urine glucose, trigonelline and trimethylamine N-oxide levels showed a better discrimination between incident diabetes cases and non-cases in women (AUC = 0.874 and 0.903, p = 0.019). In men, valine and 4-hydroxyphenylacetate were found as markers of diabetes. However, ROC analysis did not reveal any improvement in discrimination based on urine metabolites. In conclusion, we confirmed the potential of metabolomics to assess the risk of type 2 diabetes and detected pronounced sex differences. Moreover, we demonstrated the practicability of spot urine samples as potential non-invasive diabetes screening approach."],["dc.identifier.doi","10.1007/s11306-015-0795-6"],["dc.identifier.isi","000360715300034"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35903"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1573-3890"],["dc.relation.issn","1573-3882"],["dc.title","Sex differences in urine metabolites related with risk of diabetes using NMR spectroscopy: results of the study of health in pomerania"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]